Johnson & Johnson (JNJ) – Pipeline growing for innovative medicines

JNJ received EU approval for PONVORY in relapsing multiple sclerosis and also a U.S. approval of RYBREVANT for the treatment of patients with locally advanced or metastatic non small cell lung cancer with epidermal factor receptor exon 20 insertion mutations.

Highlights 

Valuation

– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– DCF Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Developments
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance

CrispIdea Coverage 

No of Pages : 40